Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Alzheimer's disease (AD) is a neurodegenerative condition that affects a large number of elderly people worldwide and has a high social and economic impact.
-
Alzheimer's disease (AD), the main cause of dementia, is characterized by the aggregation of amyloid-β (Aβ).
-
As we age, we experience changes in our nighttime sleep and daytime wakefulness.
-
Cognitive impairment associated with aging has emerged as one of the major public health challenges of our time.
-
Blood-based diagnosis (hemodiagnosis) of Alzheimer's disease (AD) is emerging as a promising alternative to cerebrospinal-fluid-based methods because blood contains various kinds of AD biomarkers, including amyloid beta 1-40, 1-42, and τ (tau) protein.
-
Astrocytic contributions to Alzheimer's disease (AD) progression were, until recently, largely overlooked.
-
Biomarker discovery and development for clinical research, diagnostics and therapy monitoring in clinical trials have advanced rapidly in key areas of medicine - most notably, oncology and cardiovascular diseases - allowing rapid early detection and supporting the evolution of biomarker-guided, precision-medicine-based targeted therapies.
-
Technologies for imaging the pathophysiology of Alzheimer disease (AD) now permit studies of the relationships between the two major proteins deposited in this disease - amyloid-β (Aβ) and tau - and their effects on measures of neurodegeneration and cognition in humans.
-
Accumulating data from the clinical research support that the core Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers amyloid-β (Aβ42), total tau (T-tau), and phosphorylated tau (P-tau) reflect key elements of AD pathophysiology.
-
38/100
Tau protein plays a crucial role in the pathogenesis of Alzheimer's disease (AD).
-
Alzheimer's disease (AD), the most common type of dementia, is becoming a major challenge for global health and social care.
-
Monitoring the ratio of 40- and 42-residue amyloid β peptides (i.e., Aβ40 and Aβ42) in human plasma is considered one of the hallmarks of detection of the early stage of Alzheimer's disease (AD).
-
Traumatic brain injury (TBI) is a major worldwide neurological disorder of epidemic proportions.
-
The feasibility of assaying plasma phosphorylated tau protein (threonine 181), denoted p-tau181, using immunomagnetic reduction (IMR) is explored.
-
38/100
The past five years have seen an enormous development in the field of fluid biomarkers for Alzheimer's disease (AD) and related disorders.
-
The aberrant accumulation of the amyloid protein is a critical and early event in the Alzheimer's disease (AD) cascade.
-
High affinity of AV-1451 for monoamine oxidase proteins may limit its utility as a tau PET tracer in PSP and Alzheimer's disease because of high levels of monoamine oxidase expression in brain regions also affected by tau deposition, especially if monoamine oxidase levels change over time or with a treatment intervention. © 2017 International Parkinson and Movement Disorder Society.
-
Alzheimer's disease (AD) may affect in excess of 90% of individuals with Down syndrome (DS) after age 60, due to duplication of the APP gene in trisomy of chromosome 21, with neuropathology that is comparable to Sporadic AD and Familial AD (FAD).
-
Alzheimer's disease (AD) is characterized by two hallmark molecular pathologies: amyloid aβ 1-42 and Tau neurofibrillary tangles.
-
Normal aging is associated with a decline in episodic memory and also with aggregation of the β-amyloid (Aβ) and tau proteins and atrophy of medial temporal lobe (MTL) structures crucial to memory formation.
-
The recent failures of potential disease-modifying drugs for Alzheimer's disease (AD) may reflect the fact that the enrolled participants in clinical trials are already too advanced to derive a clinical benefit.
-
The clinical heterogeneity of Alzheimer's disease is not reflected in the rather diffuse cortical deposition of amyloid-β.
-
38/100
Amyloid-related imaging abnormalities (ARIA) in magnetic resonance imaging scans have emerged as indicators of potentially serious side effects in clinical trials of therapeutics for Alzheimer's disease.
-
Alzheimer's disease (AD) is a progressive neurodegenerative disorder resulting in dementia and eventual death.
-
We studied neuroinflammation in individuals with late-life depression, as a risk factor for dementia, using [11C]PK11195 positron emission tomography (PET).
From across this topic
10 of the 1,573 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Blood Protein Markers of Neocortical Amyloid-β Burden: A Candidate Study Using SOMAscan Technology
- Optic nerve damage in Alzheimer's disease
- A novel blood test for the early detection of Alzheimer's disease
- Plasma biomarkers and incident clinical stage progression in the specialized memory clinic: a longitudinal study
- Performance of plasma p-tau217 and NfL in an unselected memory clinic setting
- Clinical performance and robustness evaluation of plasma amyloid-β42/40 prescreening
- Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP
- Polygenic risk score predicts pathologically confirmed cerebral amyloid angiopathy
- Amyloid-beta42 plasma levels are elevated in amnestic mild cognitive impairment
- Alzheimer's disease in Down syndrome: neurobiology and risk